6-苯甲基-6-氮杂二环[3.2.1]辛烷-3-酮 | 16607-47-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 6-苯甲基-6-氮杂二环[3.2.1]辛烷-3-酮
• 英文名称: 6-Benzyl-3-oxo-6-azabicyclo<3.2.1>octan
• 英文别名: 6-benzyl-6-azabicyclo[3.2.1]octan-3-one
• CAS: 16607-47-9
• 化学式: C₁₄H₁₇NO
• 分子量: 215.295
• InChiKey: REVWWFCQBQDVEN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  20.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  6-苯甲基-6-氮杂二环[3.2.1]辛烷-3-酮 在 sodium tetrahydroborate 作用下， 以 甲醇 为溶剂， 反应 0.25h， 以96%的产率得到(+/-)-6-Benzyl-6-azabiyclo<3.2.1>octan-3β-ol
  参考文献：
  名称：

  Pitner, J. Bruce; Abraham, Philip; Joo, Young J., Journal of the Chemical Society. Perkin transactions I, 1991, # 6, p. 1375 - 1381

  摘要：

  DOI：
• 作为产物：
  描述：

  6-氧杂双环[3.2.1]辛-3-烯-7-酮 在 manganese(IV) oxide 、 lithium aluminium tetrahydride 作用下， 以 四氢呋喃 、 二氯甲烷 、 xylene 为溶剂， 反应 30.2h， 生成 6-苯甲基-6-氮杂二环[3.2.1]辛烷-3-酮
  参考文献：
  名称：

  Pitner, J. Bruce; Abraham, Philip; Joo, Young J., Journal of the Chemical Society. Perkin transactions I, 1991, # 6, p. 1375 - 1381

  摘要：

  DOI：

文献信息

• Nicotinic Acetylcholine Receptor Modulators
  申请人：Jiang Faming

  公开号：US20090118326A1

  公开（公告）日：2009-05-07

  The disclosure provides compounds capable of selectively or non-selectively modulating nicotinic acetylcholine receptors. The compounds, compositions, and methods described herein are useful, for example, in treating patients suffering from various medical conditions including pain, chemical addictions, Parkinson's disease, Alzheimer's disease, and neurodegenerative disorders. In one embodiment, the compounds comprise a 7- to 11-membered azabicyclo ring.

  该披露提供了能够选择性或非选择性调节尼古丁乙酰胆碱受体的化合物。这里描述的化合物、组合物和方法在治疗患有各种疾病的患者方面是有用的，包括疼痛、化学成瘾、帕金森病、阿尔茨海默病和神经退行性疾病。在一个实施例中，这些化合物包括一个由7到11个成员的氮杂双环环。
• [EN] NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS<br/>[FR] MODULATEURS DES RÉCEPTEURS NICOTINIQUES DE L'ACÉTYLCHOLINE
  申请人：STANFORD RES INST INT

  公开号：WO2009058120A1

  公开（公告）日：2009-05-07

  The disclosure provides compounds capable of selectively or non-selectively modulating nicotinic acetylcholine receptors. The compounds, compositions, and methods described herein are useful, for example, in treating patients suffering from various medical conditions including pain, chemical addictions, Parkinson's disease, Alzheimer's disease, and neurodegenerative disorders. In one embodiment, the compounds comprise a 7- to 1 1 - membered azabicyclo ring.

  该披露提供了能够选择性或非选择性调节尼古丁乙酰胆碱受体的化合物。这里描述的化合物、组合物和方法在治疗患有各种疾病的患者中很有用，包括疼痛、化学成瘾、帕金森病、阿尔茨海默病和神经退行性疾病。在一个实施例中，这些化合物包括一个由7到11个成员的氮杂双环环。
• PHARMACEUTICAL COMPOSITIONS AND METHODS FOR RELIEVING PAIN AND TREATING CENTRAL NERVOUS SYSTEM DISORDERS
  申请人：Breining R. Scott

  公开号：US20050282823A1

  公开（公告）日：2005-12-22

  Patients susceptible to or suffering from disorders, such as central nervous system disorders, which are characterized by an alteration in normal neurotransmitter release, such as dopamine release (e.g., Parkinsonism, Parkinson's Disease, Tourette's Syndrome, attention deficient disorder, or schizophrenia), are treated by administering a compound of Formulas 1 or 2, as described herein. The compounds of Formulas 1 and 2 are also useful for treating pain, and treating drug addiction, nicotine addiction, and/or obesity. The compounds can exist as individual stereoisomers, racemic mixtures, diastereomers and the like.

  对于易感受或患有疾病的患者，例如中枢神经系统疾病，其特征为正常神经递质释放的改变，例如多巴胺释放（例如帕金森症，帕金森氏病，抽动症，注意力缺陷障碍或精神分裂症），可以通过给予本文所述的1或2式化合物来治疗。 1和2式化合物也可用于治疗疼痛，药物成瘾，尼古丁成瘾和/或肥胖症。这些化合物可以存在于单个立体异构体，混合物，对映异构体等形式。
• Pharmaceutical Compositions and Methods for Relieving Pain and Treating Central Nervous System Disorders
  申请人：Breining Scott R.

  公开号：US20080242693A1

  公开（公告）日：2008-10-02

  Patients susceptible to or suffering from disorders, such as central nervous system disorders, which are characterized by an alteration in normal neurotransmitter release, such as dopamine release (e.g., Parkinsonism, Parkinson's Disease, Tourette's Syndrome, attention deficient disorder, or schizophrenia), are treated by administering a compound of Formulas 1 or 2, as described herein. The compounds of Formulas 1 and 2 are also useful for treating pain, and treating drug addiction, nicotine addiction, and/or obesity. The compounds can exist as individual stereoisomers, racemic mixtures, diastereomers and the like.

  患有或易感染神经系统紊乱（例如帕金森氏症、多动症、注意力缺陷障碍、精神分裂症等）的患者，其特征为神经递质释放（例如多巴胺释放）的异常改变，可通过给予本文所述的1或2式化合物治疗。1和2式化合物也可用于治疗疼痛、药物成瘾、尼古丁成瘾和/或肥胖症。这些化合物可以存在为单一立体异构体、混合物、对映异构体等形式。
• Pharmaceutical compositions and methods for relieving pain and treating central nervous system disorders
  申请人：Targacept, Inc.

  公开号：US07402592B2

  公开（公告）日：2008-07-22

  Patients susceptible to or suffering from disorders, such as central nervous system disorders, which are characterized by an alteration in normal neurotransmitter release, such as dopamine release (e.g., Parkinsonism, Parkinson's Disease, Tourette's Syndrome, attention deficient disorder, or schizophrenia), are treated by administering a compound of Formulas 1 or 2, as described herein. The compounds of Formulas 1 and 2 are also useful for treating pain, and treating drug addiction, nicotine addiction, and/or obesity. The compounds can exist as individual stereoisomers, racemic mixtures, diastereomers and the like.

  易感受或患有诸如中枢神经系统失调的疾病的患者，这些疾病的特征是神经递质的正常释放发生改变，例如多巴胺释放（例如帕金森症，帕金森氏病，抽动症，注意力缺陷障碍或精神分裂症），通过给予本文中所描述的1或2号配方的化合物进行治疗。 公式1和2的化合物还可用于治疗疼痛，药物成瘾，尼古丁成瘾和/或肥胖症。 这些化合物可以存在于单个立体异构体，混合物，对映异构体等形式。